A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell...

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• GATA-3 is highly expressed in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphomas (PTCL), contributing to chemotherapy resistance.
• GATA-3 expression is transcriptionally regulated by NF-κB, a key pathway in T-cell malignancies.

Purpose of the Study:

• To investigate the efficacy of proteasome inhibition, specifically using ixazomib, in impairing NF-κB activation, GATA-3 expression, and cell viability in malignant T cells.
• To evaluate ixazomib in a phase II clinical trial for patients with relapsed/refractory CTCL/PTCL.

Main Methods:

• Ex vivo treatment of patient-derived cell lines and primary T-cell lymphoma specimens with ixazomib.
• Assessment of proteasome inhibition, NF-κB activity, GATA-3 expression, and cell viability.
• A single-center, phase II clinical study of ixazomib in patients with relapsed/refractory CTCL/PTCL.

Main Results:

• Preclinical studies showed significant reductions in cell viability, NF-κB activation, and GATA-3 expression upon ixazomib treatment.
• In a phase II trial, a significant reduction in NF-κB activation and GATA-3 expression was observed in an exceptional responder after one month of ixazomib.
• Ixazomib demonstrated limited overall activity in the small, heterogeneous patient cohort.

Conclusions:

• Inhibition of the NF-κB/GATA-3 axis by ixazomib shows promise, as evidenced by preclinical data and an exceptional responder.
• Ixazomib may hold potential utility for CTCL/PTCL treatment in carefully selected patient populations or in combination therapies.